SER33 Antibody

What is the biological significance of RPA2-Ser33 phosphorylation?

RPA2-Ser33 phosphorylation serves as an early marker of DNA damage response activation. As part of the heterotrimeric replication protein A complex (RPA/RP-A), RPA2 binds and stabilizes single-stranded DNA intermediates formed during DNA replication or upon DNA stress. This phosphorylation event plays an essential role in both DNA replication and cellular response to DNA damage . Specifically, Ser33 phosphorylation is mediated by ATR kinase and serves as a priming event that facilitates subsequent phosphorylation at other sites on the RPA2 N-terminus . This cascade of phosphorylation events controls DNA repair and damage checkpoint activation, particularly through recruitment of DNA double-strand break repair factors like RAD51 and RAD52 to chromatin .

What are the recommended applications for Anti-Phospho-RPA2-Ser33 antibodies?

Anti-Phospho-RPA2-Ser33 antibodies are suitable for multiple research applications with specific recommended dilutions:

These applications allow researchers to detect endogenous levels of RPA2 protein specifically when it is phosphorylated at Ser33 . The antibody specificity ensures that only the phosphorylated form is detected, making it valuable for studying DNA damage response pathways.

What are the optimal storage conditions for Anti-Phospho-RPA2-Ser33 antibodies?

For maximum stability and activity retention, Anti-Phospho-RPA2-Ser33 antibodies should be stored at -20°C for up to one year from the date of receipt . It is crucial to avoid repeated freeze-thaw cycles as these can compromise antibody performance. Most commercial preparations are supplied in phosphate-buffered saline (PBS) containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain antibody stability during storage . When working with the antibody, aliquoting into smaller volumes is recommended to minimize freeze-thaw cycles.

How should I induce RPA2-Ser33 phosphorylation in cell culture models?

To induce RPA2-Ser33 phosphorylation for experimental purposes, several DNA-damaging agents and replication stress inducers have been validated in the literature:

• Etoposide (100 μM for 16 hours) - Effectively induces RPA2-Ser33 phosphorylation in HeLa cells as demonstrated by Western blot analysis .

• Hydroxyurea (5 mM for 2 hours) - Produces clear nuclear staining of phosphorylated RPA2-Ser33 in PDAC cells as visualized by immunofluorescence .

• Ionizing radiation (IR) - Induces RPA2-NT phosphorylation, with Ser33 being one of the primary sites. This phosphorylation is delayed in cells with inactive ATM kinase .

When designing experiments, include both treated and untreated control samples to confirm specificity of the phosphorylation signal. The choice of induction method should align with the specific DNA damage pathway being investigated, as different agents may activate distinct signaling mechanisms.

What controls should be included when using Anti-Phospho-RPA2-Ser33 antibodies?

To ensure experimental rigor and proper interpretation of results, include the following controls:

• Negative control: Untreated cell lysates to establish baseline phosphorylation levels.

• Positive control: Lysates from cells treated with known inducers of RPA2-Ser33 phosphorylation (e.g., etoposide, hydroxyurea, or IR).

• Phosphatase treatment control: Treating a portion of your positive control sample with lambda phosphatase will confirm antibody phospho-specificity.

• Total RPA2 antibody: Running parallel blots or sequential probing with an antibody that detects total RPA2 regardless of phosphorylation status will help normalize results and confirm that observed changes are due to phosphorylation rather than altered protein expression.

• Loading control: Use of housekeeping proteins (e.g., RPS3 as shown in published studies) ensures equal protein loading across samples .

These controls are essential for validating antibody specificity and correctly interpreting experimental results, particularly when studying stress-induced phosphorylation events.

How can I optimize Western blot conditions for detecting phosphorylated RPA2-Ser33?

Optimizing Western blot conditions for phospho-specific antibodies requires attention to several technical aspects:

• Sample preparation: Immediately after cell treatment, lyse cells in buffer containing phosphatase inhibitors to preserve phosphorylation status.

• Protein amount: Load 50 μg of whole cell lysate as a starting point, which has been shown effective in published protocols .

• Antibody dilution: Start with a 1:1000 dilution for Western blot applications, but be prepared to optimize within the range of 1:500-1:2000 .

• Exposure time: Expect to use exposure times around 3 minutes for chemiluminescence detection, though this will vary by system and signal strength .

• Multiple bands: Be aware that numerous bands representing proteins that migrate more slowly than 60-70 kDa have been observed. Under some conditions, at least two of these may be more intense than the band representing phospho-RPA32-S33 .

• Blocking conditions: Use 5% BSA rather than milk for blocking, as milk contains casein phosphoproteins that may interfere with phospho-antibody binding.

• Signal enhancement: Consider using enhanced chemiluminescence substrates specifically designed for detecting phosphorylated proteins.

How does HERC2 regulate RPA2-Ser33 phosphorylation?

HERC2, an E3 ubiquitin ligase, plays dual roles in regulating RPA2-Ser33 phosphorylation through a sophisticated mechanism:

• Induction of phosphorylation: HERC2 is essential for ATR-mediated phosphorylation of RPA2 at Ser33 induced by low-level replication stress. When HERC2 is depleted, this phosphorylation is inhibited .

• Degradation of phosphorylated form: HERC2 also mediates the ubiquitination of phosphorylated RPA2, targeting it for degradation. This ubiquitination is dependent on ATR activity, as treatment with ATR inhibitors abolishes HERC2-mediated ubiquitination of RPA2 .

• Fine-tuning mechanism: Cells lacking HERC2 catalytic residues constitutively express increased levels of Ser33-phosphorylated RPA2, suggesting that HERC2 acts as a fine-tuning mechanism that both induces and degrades ATR-phosphorylated RPA2 .

• Functional significance: This regulatory mechanism is critical for suppressing secondary DNA structures, particularly G-quadruplex (G4) DNA, during cell proliferation. HERC2 has an epistatic relationship with RPA in G4 suppression, as determined through siRNA knockdown experiments .

This complex regulation demonstrates how phosphorylation events must be precisely controlled both temporally and spatially during DNA damage response.

What is the temporal sequence of RPA2 phosphorylation events following DNA damage?

RPA2 undergoes a specific sequence of phosphorylation events following DNA damage, with Ser33 phosphorylation playing a key priming role:

• Initial phosphorylation: Ser33 is phosphorylated by ATR kinase as one of the earliest events in response to DNA damage or replication stress .

• Priming effect: Ser33 phosphorylation stimulates subsequent phosphorylation at other sites (Ser4, Ser8, Ser12, Thr21) on the RPA2 N-terminus .

• Reciprocal priming: The RPA2-NT sites show reciprocal priming effects. For example, mutation of Thr21 to Alanine reduces Ser4/8 phosphorylation and vice versa, indicating complex interdependence .

• Late-stage phosphorylation: Ser12 phosphorylation occurs at later time points than the other RPA2-NT sites, suggesting different timing for different phosphorylation events .

• Cell cycle-dependent phosphorylation: Additionally, residues Ser23 and Ser29 are known cyclin-dependent kinase (CDK) sites. Ser29 has been shown to be mitotically phosphorylated, whereas Ser23 phosphorylation has been observed in both mitosis and S phase .

Understanding this temporal sequence is crucial for interpreting experimental results and designing time-course studies of DNA damage response.

How does RPA2-Ser33 phosphorylation contribute to DNA repair pathway choice?

Phosphorylation of RPA2 at Ser33 influences DNA repair pathway selection through several mechanisms:

• Homologous recombination (HR) pathway: Phosphorylated RPA2 preferentially localizes to double-strand break (DSB) repair complexes, enhancing co-immunoprecipitation with RAD51 and RAD52 and colocalization with RAD52 and ATR in nuclear foci .

• Pathway regulation: RPA2 phosphorylation regulates the transfer of single-stranded DNA from RPA to RAD52, a critical step in HR repair pathways .

• Pathway choice: RPA2 participates in two HR sub-pathways: genetic conversion (GC) and single-strand annealing (SSA). In GC, BRCA2 displaces RPA from ssDNA at DSB ends and loads RAD51. Alternatively, RPA and RAD52 can repair DSBs using the more error-prone SSA pathway .

• Chromosomal DNA repair facilitation: Phosphorylated RPA2 has been reported to facilitate chromosomal DNA repair while preventing RPA from associating with replication centers in human cells .

• ATM dependency: RPA2-NT phosphorylation in response to ionizing radiation is delayed in cells with inactive ATM kinase, suggesting a complex interplay between ATM and ATR signaling in regulating RPA2 function in DNA repair .

This regulatory mechanism ensures that appropriate repair pathways are activated based on the type and context of DNA damage, contributing to genome stability maintenance.

Why might I observe additional bands when using Anti-Phospho-RPA2-Ser33 antibodies in Western blot?

When working with Anti-Phospho-RPA2-Ser33 antibodies, you may observe multiple bands that require careful interpretation:

• Higher molecular weight bands: Numerous bands representing proteins that migrate more slowly than 60-70 kDa have been observed. Under some conditions, at least two of these may be more intense than the band representing phospho-RPA32-S33 .

• Potential causes:

  • Ubiquitinated forms of phosphorylated RPA2, as HERC2 has been shown to ubiquitinate RPA2 in an ATR-dependent manner

  • Additional post-translational modifications besides phosphorylation

  • RPA2 interactions with other proteins that resist denaturation

  • Cross-reactivity with other phosphorylated proteins

• Verification approaches:

  • Confirm specificity using phosphatase treatment of lysates

  • Include RPA2 knockdown controls

  • Compare band patterns between different phospho-RPA2 antibodies

  • Perform immunoprecipitation followed by mass spectrometry to identify additional bands

• Experimental significance: The presence of higher molecular weight bands may actually provide insights into the regulation of RPA2, particularly regarding its ubiquitination by HERC2 as part of the fine-tuning mechanism for RPA2 levels after DNA damage .

How can I distinguish between different phosphorylation states of RPA2 in my experiments?

Distinguishing between various phosphorylation states of RPA2 requires strategic experimental design:

• Site-specific phospho-antibodies: Use antibodies specifically targeting distinct phosphorylation sites (Ser4, Ser8, Ser12, Thr21, Ser33) to track individual phosphorylation events .

• Phosphorylation-specific mobility shifts: Different phosphorylation states of RPA2 can be visualized as distinct mobility shifts on SDS-PAGE. The hyperphosphorylated form typically migrates more slowly than the unphosphorylated or partially phosphorylated forms.

• Phospho-mutant constructs: Generate RPA2 constructs with serine-to-alanine mutations at specific phosphorylation sites to prevent phosphorylation at those positions and determine their functional significance.

• Kinase inhibitors: Use specific inhibitors of ATR (for Ser33), ATM, or CDKs to block particular phosphorylation events and observe the resulting patterns:

  • ATR inhibitors will prevent Ser33 phosphorylation

  • CDK inhibitors will block Ser23 and Ser29 phosphorylation

  • ATM inhibitors will affect the phosphorylation cascade differently than ATR inhibitors

• Temporal analysis: Design time-course experiments after DNA damage induction to capture the sequential nature of RPA2 phosphorylation, where Ser33 phosphorylation precedes and enables other phosphorylation events .

What are the potential artifacts or misinterpretations when studying RPA2-Ser33 phosphorylation in cancer cells?

When investigating RPA2-Ser33 phosphorylation in cancer cells, researchers should be aware of several potential artifacts and misinterpretations:

• Constitutive phosphorylation in cancer cells: Some cancer cell lines exhibit elevated basal levels of RPA2-Ser33 phosphorylation due to ongoing replication stress, which may mask treatment-induced changes.

• Cell cycle effects: As RPA2 also undergoes cell cycle-dependent phosphorylation (particularly at Ser23 and Ser29), differences in cell cycle distribution between samples can confound interpretation of damage-specific phosphorylation at Ser33 .

• Cross-reactivity considerations: Antibody cross-reactivity with other phosphorylated proteins may occur, particularly in cancer cells with dysregulated kinase activities.

• Altered HERC2 activity: Cancer cells with mutations affecting HERC2 E3 ligase activity may show abnormal patterns of RPA2-Ser33 phosphorylation due to disrupted fine-tuning mechanisms .

• Contextual interpretation: The biological significance of RPA2-Ser33 phosphorylation may differ between cancer types or genetic backgrounds. For example, cells lacking functional ATM may show delayed RPA2 phosphorylation patterns after ionizing radiation .

• Therapeutic implications: Cancer cells with defects in the RPA2 phosphorylation pathway may respond differently to genotoxic therapies, making accurate assessment of phosphorylation status important for predicting treatment outcomes.

To mitigate these potential issues, always include appropriate controls, consider cell cycle synchronization where necessary, and validate findings across multiple cell lines or patient-derived samples.

How might RPA2-Ser33 phosphorylation be exploited as a biomarker in cancer research?

RPA2-Ser33 phosphorylation holds significant potential as a biomarker in cancer research through several applications:

• DNA damage response assessment: As RPA2-Ser33 phosphorylation is an early event in the DNA damage response, it could serve as a sensitive marker for assessing endogenous replication stress levels in different cancer types.

• Treatment response monitoring: Changes in RPA2-Ser33 phosphorylation following chemotherapy or radiation could provide real-time feedback on treatment efficacy, particularly for agents that induce replication stress or DNA damage.

• Patient stratification: Differential patterns of RPA2-Ser33 phosphorylation might identify patient subgroups likely to respond to specific therapeutic approaches, especially those targeting DNA repair pathways.

• Combination therapy rationale: Understanding how RPA2-Ser33 phosphorylation is regulated by HERC2 and ATR provides a mechanistic basis for combining ATR inhibitors with other therapeutic agents to maximize efficacy .

• Resistance mechanisms: Altered patterns of RPA2-Ser33 phosphorylation might indicate adaptation or resistance mechanisms in cancer cells exposed to genotoxic therapies.

Future research should focus on standardizing detection methods for clinical samples and correlating phosphorylation status with clinical outcomes across diverse cancer types and treatment regimens.

What methodological advances could improve the study of dynamic RPA2 phosphorylation events?

Advancing our understanding of dynamic RPA2 phosphorylation requires innovative methodological approaches:

These methodological advances would address current limitations in temporal resolution, sensitivity, and comprehensiveness of RPA2 phosphorylation analysis.